Business Wire

Mary Kay Inc. Caps Off Landmark Scientific Credentialing Year at 73rd Society of Cosmetic Chemists Meeting

20.12.2019 17:00:00 EET | Business Wire | Press release

Share

In 2019, Mary Kay Inc. continued its decades-long commitment to skin science research by revealing the results of multiple groundbreaking studies and fostering academic discussion with industry peers at scientific symposiums around the globe. Most recently, Mary Kay was in New York City for the 73rd Society of Cosmetic Chemists Meeting, where the brand sponsored, collaborated, and explored applications of skin microbiome with leading experts in the field.

“New research suggests that microbes play an important role in overall skin health, and as leading skincare innovators, Mary Kay is heavily invested in further exploration of their impact,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay. “We have a commitment to take an active role in the beauty and scientific communities through participation in global dermatological conferences like the Society of Cosmetic Chemists Meeting, where we can share and learn from other scientific experts to help us develop more effective products.”

The Society of Cosmetic Chemists Meeting convenes over 1,300 attendees from some of the top cosmetic and personal care brands and manufacturers. Participants are encouraged to engage with speakers presenting the latest research and innovations of interest to cosmetic scientists, exchange ideas with peers, and reconnect with colleagues from around the globe.

Mary Kay sponsored the educational session at the meeting, including topics Quorum Quenching: the New Way to Keep Microbiome Under Control, Exploring New Applications in Personal Care: Balancing our Skin Microbiota, Global Microbiome Effects, and Temporal Variation of the Facial Skin Microbiome.

Additional 2019 Scientific Research and Credentialing

The 73rd Society of Chemists Meeting is the latest event in a series of Mary Kay presentations with the scientific and academic communities that reinforce the brand’s longstanding commitment to advancing skin health research and development. Every year, Mary Kay conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio. Recently, the company announced the opening of a more than $100 million state-of-the-art manufacturing and R&D facility in Lewisville, Texas.

In 2019, Mary Kay focused on three pillars in its commitment to skin health, including pollution; skin barrier health and sensitive skin; and the understanding of skin aging and strategies to intervene:

Pollution and Skin Health

  • May: Mary Kay sponsored an exclusive symposium on the impact of pollution on skin health in the Latin America region at the prestigious Reunión Anual de Dermatólogos Latinoamericanos (RADLA) in Buenos Aires, Argentina. Dr. Gildea moderated this symposium with 3 expert Brazilian dermatologists sharing research on the impact of air pollution on skin. It was concluded that antioxidants would be a viable way to counteract the negative effects of pollution on skin. Fortunately, Mary Kay also presented findings on an antioxidant complex that can help delay the premature signs of aging related to the damaging effects of air pollution.
  • June: Mary Kay the 24th World Congress of Dermatology in Milan, Italy. Mary Kay sponsored a Questions and Answers session with 2 dermatology experts on the impact of environmental stressors in Europe on skin. Dr. Michelle Hines, Global Upstream Research & Technology at Mary Kay hosted this event featuring two renowned Europe skin experts:
    • Jean Krutmann, M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
    • Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
  • June: At the 5th Future of Formulations in Cosmetics Summit in Dusseldorf, Germany, Dr. Hines revealed Mary Kay’s ongoing research on an antioxidant complex that helps delay the onset of premature signs of aging related to the damaging effects of diesel exhaust particles (DEP) on skin cells. The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D™ skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.

Skin Barrier Health and Sensitive Skin

  • March: At the 20th World Dermatology Congress in Singapore, David Gan, Senior Principal Scientist at Mary Kay Inc., presented some new insights in evaluating and understanding facial redness. Based on this work, Mary Kay scientists identified skincare technology that helps reduce the production of pro-inflammatory proteins and enzymes in the skin and developed a cosmetic formulation containing these ingredients to effectively address facial redness using unique clinical measures.
  • August: Mary Kay China’s Sr. Manager for Medical Affairs, Dr. Jenny Jiang, shared some strategies from Mary Kay research to improve the skin barrier function and facial redness at the Annual Meeting of the Dermatology Committee organized by the Chinese Association of Integrative Medicine in Lanzhou, Gansu Province, China. These findings may provide important insights to understanding sensitive skin.
  • November: Mary Kay was a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID) in Aomori, Japan. Dr. Gildea moderated an educational symposium exploring environmental protection strategies against skin aging in Asians, protein response to skin inflammation and skin barrier defects. The panel featured three renowned dermatologists:
    • Dr. Akimichi Morita, MD Ph.D., Department of Geriatric and Environmental Dermatology at Nagoya City University Graduate School of Medical Sciences
    • Dr. Sang Eun Lee, MD Ph.D., Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine in Seoul, Korea
    • Dr. Gyohei Egawa, MD Ph.D., Department of Dermatology, Kyoto University Graduate School of Medicine

Understanding of Skin Aging and Skin Health and Strategies to Intervene

  • March: At the Skin of Color Society Symposium in Washington. D.C., Dr. Shoná Burkes-Henderson, Associate Principal Scientist, Clinical Research, revealed new research on navy bean extract and its ability to regulate melanogenesis, leading to an improvement in uneven skin tone and facial hyperpigmentation. Dr. Burkes-Henderson also presented a new approach to help improve facial erythema, or redness, at the American Academy of Dermatology Annual Meeting.
  • May: Mary Kay Associate Principal Scientist Dr. Tiffany Carle attended 77th Annual Meeting of the Society for Investigative Dermatology in Chicago, where she presented new data from analyzing the effects of a serum containing five botanical fruit extracts known to be rich in vitamin C on skin appearance. As part of this study, Mary Kay researchers treated artificial skin tissue with this serum and utilized a genomic approach to understand how the serum affected the skin.
  • June: Mary Kay sponsored the University of the Philippines Medical Alumni Society of America (UPMASA) 34th Annual Grand Convention (AGC) in Dallas. The conference convened more than 500 doctors from the U.S. and the Philippines to discuss topics ranging from dermatology to orthopedics and neurology.
  • September: Mary Kay shared its latest research targeting the causes and underlying mechanisms of slackened skin at the 49th Annual Meeting of the European Society for Dermatological Research (ESDR) held in Bordeaux, France. Dr. Michelle Hines shared data on technology that targeted slackened skin leading to improvement in skin clinical measures.
  • September: Mary Kay presented findings on research experiments that demonstrated how sunscreen viscosity, a property that effects application to skin, can be adjusted using processing parameters at the 2019 Sunscreen Symposium presented by the Florida chapter of the Society of Cosmetic Chemists in Lake Buena Vista, Florida.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers

Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release

At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project

NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa

MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release

MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg

Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release

Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye